ASCIMINIB HYDROCHLORIDE, ASCIMINIB
CABL001A2302
Phase 3 small_molecule active
Quick answer
ASCIMINIB HYDROCHLORIDE, ASCIMINIB for Chronic Myelogenous Leukemia in chronic phase (CML-CP) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Chronic Myelogenous Leukemia in chronic phase (CML-CP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active